| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.5 | 41.9 |
| Profit before tax | -53.7 | -34.8 |
| Net income | -53.9 | -35.1 |
| EPS (diluted, $ a share) | $-0.82 | $-0.48 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -98.8% |
|---|
10-Q filed with the SEC, NASDAQ: ARVN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Arvinas, Inc.: key numbers
- Share price
- $6.77Close, Nov 16
- Market cap
- $443M
- Shares outstanding
- 65.49MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Arvinas, Inc.
All →Arvinas Financial Results
Arvinas reported third quarter 2026 financial results and provided a corporate update on its protein degrader pipeline, including the initiation of a Phase 1/2 trial for its HPK1 degrader ARV-6723. The company ended the quarter with $1.1 billion in cash and equivalents, which it expects will fund operations into 2028. Key upcoming milestones include Phase 1 data readouts for ARV-393, ARV-027, and ARV-6723 through 2027.
“We executed strongly during the quarter and are entering an important period of clinical milestones that we believe will demonstrate the promise of our clinical-stage protein degraders. We are prioritizing investments where emerging evidence supports our goal of creating transformative medicines for patients. The upcoming data from our BCL6, polyQ-AR, and HPK1 degraders will begin to define the opportunity for these programs to change the treatment landscape, and we are grateful to the patients, investigators, and employees whose commitment makes this progress possible.”
Randy Teel, Ph.D., President and Chief Executive Officer of Arvinas